Palantir Soars in Tech Talk, Shares Slip Premarket
Palantir (NASDAQ:PLTR) fires on nearly all cylinders in Q1, delivering over 30% top-line growth and an 83% rule-of-40 score even as shares slipped more than 7% in premarket trading.
Analysts at Wedbush Securities lifted their price target to $140 from $120, calling Palantir a generational tech name poised for a trillion-dollar market cap within three years after the company beat guidance and raised its outlook for fiscal 2025.
Josh Arnold of Timely Trader echoed the sentiment, calling the results another blowout and highlighting that free cash flow and operating profit guidance rose well ahead of revenue growth, implying significant runway for operating leverage going forward, though he warned valuation is catching up to fundamentals.
Morgan Stanley's Sanjit Singh agreed that Palantir is firing on nearly all cylinders, praising accelerating deal closures in both government and commercial markets amid broader macro uncertainty.
Singh kept an Equal-Weight rating but nudged his price target up to $98 from $90, citing 30%+ revenue growth and an 83% rule-of-40 score as evidence that Palantir has cemented its status as an AI software leader. Bank of America's Mariana Perez Mora maintained her Buy rating, noting that strong demand across segments drove the topline beat and continues to accelerate growth rates.
Why it matters: Palantir's Q1 performance reinforces its AI-driven growth story and operating leverage potential, but the premarket stock dip signals that investors remain wary of the premium valuation.
Investors will now focus on Q2 guidance and the pace of large deal closures in government and commercial pipelines when Palantir reports next quarter results.
This article first appeared on GuruFocus.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)
Two-year agreement expands Meridianbet and Golden Matrix's (GMGI) sports sponsorship portfolio across regulated European markets Aquatic Sports Association of Malta VALLETTA, Malta, June 04, 2025 (GLOBE NEWSWIRE) -- Meridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (NASDAQ: GMGI), a leading developer and licensor of B2B and B2C gaming platforms, today announced the signing of a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta. Under the terms of the agreement, Meridianbet becomes the exclusive betting partner of ASA, gaining integrated brand exposure across ASA events, digital platforms, and physical venues. The sponsorship includes the launch of the branded national cup competition - Meridianbet Super Cup, as well as LED road signage, scoreboard branding, and apparel sponsorships across Malta's aquatic sports federations. 'Water polo and aquatic sports are a vital part of Malta's sporting culture,' said Stefan Pavlovic, Malta territory director at Meridianbet. 'This partnership reflects our continued commitment to supporting national sports ecosystems, building long-term brand visibility in regulated markets, and delivering value to fans, players, local institutions and shareholders.' The ASA partnership builds on Meridianbet's growing sponsorship portfolio across 25+ international jurisdictions, where it supports sports ranging from football, basketball and MMA to eSports and grassroots competitions. This announcement also aligns with Meridianbet's broader ESG strategy. In 2024 alone, the company conducted 293 community engagement initiatives, reaching over 18,000 direct and indirect beneficiaries through education, healthcare, sports, and advocacy programs. Key Highlights of the Deal: Meridianbet named exclusive betting partner of Malta's ASA (governing body for water polo, swimming, artistic swimming) Launch of the Meridianbet Super Cup Brand exposure via LED ads, digital platforms, and team apparel To learn more about Meridianbet's community impact programs, visit About Meridianbet Founded in 2001, Meridianbet Group is a well-established online sports betting and gaming group, licensed and currently operating in 18 jurisdictions across Europe, Africa, and South America. The Meridianbet Group's successful business model utilizes proprietary technology and scalable systems, allowing it to operate in multiple countries and currencies with an omni-channel approach to markets, including retail, desktop online, and mobile. The Company is part of the Golden Matrix Group (Nasdaq: GMGI). For more information, visit IR Presentation - YouTube - Twitter - Email: ir@ A photo accompanying this announcement is available at
Yahoo
11 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Miami Herald
28 minutes ago
- Miami Herald
CrowdStrike stock tumbles on disappointing forecast
Nothing in computer-related work is more frustrating than getting hacked or your workflow being wrecked by an update. "My engineers do not have this problem, and now I look like a stupid sales person" was the best nontechnical person's comment I've ever heard while I was working in IT. An update broke her workflow, and she shouldn't need to be an engineer for updates to work. If you are running a company and an update for a software you rely on to keep your data safe ends up making your employee computers unbootable, what are you going to do once the issue is resolved? You might start looking elsewhere. After all, changing the cybersecurity software platform you are using is much easier than switching to a different operating system. In July 2024, CrowdStrike (CRWD) released an update that caused hundreds of millions of computers running on Microsoft (MSFT) Windows to be stuck on a recovery page with the so-called Blue Screen of Death. The company implemented a commitment plan to reassure its customers. The plan cost about $60 million. On June 3 CrowdStrike reported its earnings results for Q1 of fiscal year 2026. here are the highlights: Total revenue was $1.1 billion, a 20% increase from $921 million in the first quarter of fiscal 2025. GAAP net loss attributable to CrowdStrike was $110.2 million, compared with GAAP net income of $42.8 million a year net loss per share was 44 cents against GAAP net income of 17 cents a year earlier. Net cash generated from operations was a record $384.1 million, compared qith $383.2 million, a year cash flow was $279.4 million, compared with $322.5 million in Q1 of fiscal and equivalents grew to a record $4.61 billion as of April 30. Related: Palantir's stock price surges on AI news, gamma squeeze The company ended its customer commitment packages program in the fiscal fourth quarter, but it still reduced revenue-growth opportunities. And its forecast for second-quarter revenue came in below analysts' estimates, writes Reuters. At last check CRWD shares were trading off 5.4% above $462, More Tech Stocks: Palantir gets great news from the PentagonAnalyst has blunt words on Trump's iPhone tariff plansOpenAI teams up with legendary Apple exec CrowdStrike reported that it surpassed $1 billion in total revenue, through its partnership with GuidePoint Security. Demand for the Falcon platform is surging, the company said. Related: Popular cloud storage service might be oversharing your data "GuidePoint has been a longstanding and trusted partner in our ecosystem, consistently delivering the expertise and services customers need to unlock the full potential of the Falcon platform," said Daniel Bernard, chief business officer at CrowdStrike. "Their focus on Falcon Next-Gen security information and even management and recognition of the transformative value of Falcon Flex have enabled customers to streamline security operations, consolidate costs and stay ahead of evolving threats." Related: Nvidia, Dell announce major project to reshape AI The Arena Media Brands, LLC THESTREET is a registered trademark of TheStreet, Inc.
